CD8A and neoplasm: CTLA-4 is crucial at the priming stage of naïve anti-tumor T cell responses by professional antigen presenting cells (APC), and therefore its blockade has the potential to generate de novo powerful CD8+ cytotoxic and CD4+ helper T cell anti-tumor effector responses.